Abstract L (leucine-favoring)-system amino acid transport is uniquely and selectively diminished in chronic lymphocytic leukemia B lymphocytes: the maximal velocity of transport is 10% of normal B lymphocytes. We examined L-system transport in chronic leukemic B lymphocytes after incubation with tetradecanoyl phorbol acetate to determine if the transport abnormality can be corrected by the apparent cell maturation induced by this agent. Amino acid uptake was measured using 2-amino-2-carboxy-bicycloheptane, an L-system specific synthetic amino acid. Marked enhancement of L-system transport occurred in each of 12 leukemic cell populations; the initial velocity of transport in phorbol ester-treated cells increased 8-fold and 14-fold at 16 and 40 h, respectively, compared with untreated cells. The V.,. of the L-system in phorbol ester-treated leukemic cells was similar to that of phorbol ester-treated normal B lymphocytes. The L-system enhancement of the leukemic cells paralleled the development of plasmacytoid features at 40 h. Uptake of leucine, a naturally occurring L-system amino acid, was also increased by tetradecanoyl phorbol acetate. Cycloheximide, 100 ,ug/ml, which inhibited over 90% of protein synthesis in phorbol ester-treated chronic leukemic cells, blocked completely the phorbol ester-induced L-system enhancement. Phorbol ester treatment restores the selective Lsystem transport defect in chronic lymphocytic leukemia B lymphocytes, and this process coincides with in vitro maturation of the leukemic cells.
Introduction
Chronic lymphocytic leukemia (CLL)' is characterized by the proliferation and accumulation of immature lymphocytes. These judged by monoclonal antibody reactivity to their surface antigens and by the type and location of immunoglobulin (1) . CLL cells have two well-characterized nonimmunologic cell membrane abnormalities: absent or diminished 5'-nucleotidase activity in most patients studied (2) and markedly diminished L (leucine-favoring)-system amino acid uptake (3, 4) . The Vmax of L-system transport in fresh CLL cells is 10% of normal blood B lymphocytes and is also significantly lower than tonsillar B lymphocytes, blood T lymphocytes, and a B cell line (Table I) . Uptake by the A (alanine-favoring)-and ASC (alanine-serine-cysteine)-systems, the two other major amino acid transport systems in mammalian cells, is normal in CLL cells as compared with other lymphocyte types (4) . Maturation of CLL B cells to a plasmacytoid phenotype can be induced in vitro by treatment with tetradecanoyl phorbol acetate (TPA) (5) (6) (7) . Plasmacytoid morphology and increased cytoplasmic immunoglobulin concentration are noted at 48 h (5), and immunoglobulin secretion occurs after longer TPA exposure (6, 7) . We have examined the kinetics of L-system amino acid transport in CLL B lymphocytes after treatment with TPA and have found marked enhancement of Lsystem transport with uptake velocities comparable with those found in TPA-treated normal B lymphocytes.
Methods
Preparation oflymphocytes. CLL lymphocytes were obtained from the blood ofchronic leukemia patients with stable disease; 10 out ofthe 12 patients studied had not received chemotherapy, and the remainder had not been treated in the previous 6 mo. Platelets were removed by centrifugation at 160 g for 15 min and aspiration of the platelet-rich supernatant fraction. The remaining buffy coat was suspended in 100 ml of tissue culture medium 199 (TC-199) containing 1% wt/vol BSA and 5 ml of packed sheep red blood cells pretreated with 2-aminoethylisothiouronium bromide. The suspension was incubated at 370C for 30 min, followed by centrifugation over Ficoll-metrizoate as previously described (4). T lymphocyte-sheep cell rosettes sedimented with the granulocytes below the Ficoll-metrizoate, and purified CLL B lymphocytes were harvested from the supernate-Ficoll interface. Cells were washed twice in TC-199, and resuspended in RPMI 1640 medium containing 20% vol/vol heat-inactivated bovine calf serum at a density of 2 X 106 lymphocytes/ml. The cell phenotype was determined using an Epics C flow cytometer (Coulter Electronics Inc., Hialeah, FL) with fluorescent monoclonal antibodies against B4, a B lymphocyte determinant; Leu 4, a T lymphocyte determinant; and Leu 1, a surface antigen found on normal T lymphocytes and CLL B lymphocytes, but absent from normal B lymphocytes (8) . The final cell suspensions contained 96% CLL B lymphocytes and 4% residual T lymphocytes.
Normal blood B lymphocytes were prepared from the plateletpheresis residues ofhealthy blood donors (9) . Lymphocytes and monocytes were isolated by step gradient centrifugation over Ficoll-metrizoate, washed once in TC-199, and separated by countercurrent centrifugal elutriation (10) . Aliquants containing > 98% lymphocytes were separated into B and T cell fractions using a nylon wool adherence technique (11) . A 60-ml polypropylene syringe was used as a (2) 969 (3) 900 (1) The data represent the mean measurements from the number of cell populations shown in parentheses. The Vn is expressed as micromoles per liter cell water per minute (4).
column and packed with 2.4 g nylon wool compacted to a volume of 24 ml with the syringe plunger. The column was heat sterilized and washed with 150 ml of TC-199 containing 5% vol/vol bovine calf serum at 370C. A 10-ml cell suspension containing 4 X 10' lymphocytes/ml in TC-199 with 10% vol/vol bovine calf serum was washed into the nylon wool using an additional 5 ml of media. The column was sealed and incubated at 370C for 45 min to allow adherence ofthe B lymphocytes. The nonadherent T lymphocytes were eluted from the column with 50 ml of media followed by an additional wash of250 ml of media. where S, the sum ofthe squared residuals, is minimized. The measured velocity, V(n), reflects the value obtained at the nth external and internal amino acid concentrations, Co,,(n) and Ci,(n), respectively. Vi of L-system amino acid uptake in TPA-treated CLL B lymphocytes was assessed with 0.1 mM BCH, an L-system specific amino acid (14) . Values The relationship of L-system enhancement to TPA concentration is illustrated in Fig. 1 . There was a modest enhancement of BCH transport at 16 and 40 h in CLL cells exposed to DMSO alone and to TPA at a concentration of 0.0005 uM. Marked transport enhancement was noted at TPA concentrations 5 0.005 ,M, and was maximal between 0.05 and 0.5 ,M. In all other experiments, 0.15 MAM TPA was used, which produced a maximal increment in transport.
The TPA-induced enhancement of L-system transport paralleled the cell maturation induced by this agent in CLL B lymphocytes (5-7). Morphologic changes were seen in 70% of TPA-treated cells at 40 h and included an increase in cell volume, an increase in nuclear parachromatin, the reappearance of nucleoli, an eccentric location of the nucleus, and an increase in cytoplasmic volume with multiple thin cytoplasmic projections (Fig. 2) . In contrast, untreated cells contained only 2 and 7% large lymphocytes at 0 and 40 h, respectively. Cell volume increased in TPA-treated CLL cells from a mean of 204 fl/cell at 2 h to 255 fl/cell at 40 h, while untreated cells did not increase in volume over 40 h (Fig. 3) . Increased cytoplasmic immunoglobulin was detected at 40 h in TPA-treated cells of three of the five patients tested using a fluorescein-labeled anti-Ig antibody. These changes are characteristic of TPA-induced maturation of CLL B lymphocytes (5) (6) (7) . TPA (Fig. 4) .
TPA effect on L-system transport in normal B lymphocytes.
The V1 of BCH uptake was determined in normal blood B lymphocytes after incubation with or without TPA for 12 h.
The V1 of 0.1 mM BCH was 300 Amol/liter cell water per TPA effect on leucine transport in CLL and normal B lymphocytes. The L-system is the primary transport carrier for the naturally occurring amino acid, leucine, in normal blood B lymphocytes, and leucine uptake is diminished in resting CLL B lymphocytes due to the low L-system activity. The V., for leucine uptake is 450 Amol/liter cell water per minute in CLL B cells as opposed to 1,686 in normal blood B cells and 1,240 in normal blood T cells (4) . Much of the existing leucine uptake in CLL B cells occurs due to compensatory transport by the ASC-system (4 liter cell water per minute in untreated cells and increased to 1,024 in TPA-treated cells (Table V) (Table V) . The L-system specific V1 for leucine was calculated from the product of the total V1 for leucine and the percent inhibition of uptake by excess BCH. The L-system specific V1 for 0.1 mM leucine in CLL B cells was 100 ,mol/liter cell water per minute, or 39% of the Vi in normal B cells, 259 ,gmol/liter cell water per minute (Table V) . TPA treatment caused an increase in the L-system specific V1 in both CLL and normal B cells. The Vi for CLL B cells increased 10-fold to 988 and the Vi for normal B cells increased 3-fold to 901 (Table V) . The L-system specific Vi for leucine in TPA-treated CLL B lymphocytes was similar to that of TPA-treated normal B lymphocytes at a physiological leucine concentration of 0.1 mM.
Cycloheximide effect on L-system transport in CLL B lymphocytes. The enhanced L-system transport in CLL cells that followed TPA treatment may have required protein synthesis, since the effect was not seen after a 2-h exposure to TPA, and (Table VI) . The Vi for CLL cells exposed to both TPA and cycloheximide was identical to that for CLL cells exposed to cycloheximide alone (Table VI) . CLL cells exposed to TPA for 12 h followed by cycloheximide exposure for 30 min showed no inhibition of L-system transport, indicating that cycloheximide did not directly inhibit the L-amino acid transport system. TPA effect on A-system transport in CLL B lymphocytes. A-system amino acid transport was assessed using the A-system specific synthetic amino acid, 2-(methylamino) isobutyric acid (methyl-AIB, 0.1 mM). The Vi of fresh CLL B cells unexposed to TPA was 22 14mol/liter cell water per minute, which is Third, the proportion of leucine uptake that occurred via the L-system increased with TPA treatment, and fourth, the magnitude of L-system specific leucine transport in TPA-treated CLL cells was similar to that of TPA-treated normal B lymphocytes. After TPA treatment, the L-system transporter in CLL B lymphocytes had an apparent increased affinity for BCH. Heightened affinity for A-system amino acids has been observed previously in CLL B lymphocytes as the cells adapted to an amino acid-deficient environment (18) . Adaptive A-system transport has been described in many cell types, and it has been suggested that a new species of carrier for A-system substrates may be synthesized in a milieu with a low amino acid concentration (18) . The reason for the increased affinity of the L-system for BCH in TPA-treated CLL cells is unclear. However, the markedly enhanced transport of 0.1 mM BCH in TPA-treated normal B lymphocytes suggests the presence of a high affinity L-system transporter in these cells as well.
The biologic response to phorbol esters in lymphocytes and other cell types is thought to result from direct activation ofthe calcium-dependent enzyme, protein kinase C, with resultant phosphorylation and activation of either intermediary or response proteins (19) (20) (21) . Several TPA-induced biological responses are rapid, such as superoxide production in human monocytes (22) and Na+/H' exchange in rat thymic lymphocytes (23) . We found that TPA-induced enhancement of Asystem amino acid uptake in CLL cells occurred after 30 min of incubation with TPA. Increased transport of neutral amino acids in bovine tonsillar lymphocytes (24) and rat thymic lymphocytes (23) also occurred within 30 min of TPA exposure, and the rapid effect in rat thymocytes was felt to be the result of direct phosphorylation of existing transport proteins (23) . In contrast, no increased L-system amino acid transport was observed in CLL B lymphocytes after a 2-h incubation with TPA. Furthermore, the cycloheximide-sensitive L-system enhancement measured at 16 and 40 h is compatible with a requirement for new protein synthesis to restore L-system transport function in the B lymphocytes of CLL. TPA may be activating an intracellular signal to enhance L-system transport that persists after potential down-regulation or degradation of protein kinase C over the 40-h period of observation.
The fundamental reason for the low L-system transport in CLL B lymphocytes is unclear. Our prior studies of L-system uptake by several normal and neoplastic lymphocyte types including T cell CLL (Sezary syndrome) have confirmed the uniqueness ofthe low L-system transport by CLL B cells (3, 4) . Cells expressing early and intermediate B lymphocyte phenotypes have recently been identified in normal human lymph nodes (25) and fetal spleen (26), but they have not been isolated in sufficient quantity and purity to study amino acid transport. We believe it improbable that CLL B cells have an order of magnitude decrease in L-system transport as an expression of cell immaturity. The fundamental importance of amino acid acquisition for the heightened protein synthesis and metabolism of young, proliferative, maturing cells would argue against such a profound decrease in uptake in immature but otherwise normal cells.
There is precedent for chemical additives correcting the maturation block of neoplastic cells and, in the process, permitting the expression of a more normal phenotype. The ability of the HL-60 progranulocytic leukemia cell line to complete maturation to neutrophilic segmented granulocytes in the presence of DMSO or to macrophages in the presence of phorbol esters is well documented (27, 28) . We believe the effect of TPA on CLL L-system transport is analogous, since its increased capacity closely parallels the induction of a phenotype that is characteristic of later cells in the B cell lineage (e.g., plasma cells).
